Sensorion (ALSEN) Corporate presentation summary

Strategic focus and expertise

• Specializes in inner-ear disorders, leveraging gene therapy and small molecule programs for hearing loss.

• Lead program SENS-601 targets GJB2-related congenital hearing loss, the most common genetic cause globally.

• SENS-401, an oral small molecule, is in clinical stage for inner-ear protection and available for partnership.

• Partnerships with leading institutions and blue-chip healthcare investors support development.

Pipeline and clinical milestones

• SENS-601 advancing for congenital, pediatric progressive, and adult-onset GJB2 hearing loss; CTA cleared in France, submissions in Canada, US, and Australia expected by end of 2026.

• First patient dosing for SENS-601 targeted by early 2027, with clinical data expected throughout 2027.

• SENS-401 completed Phase II trials in three indications; seeking partners for next development stage.

Scientific innovation and preclinical data

• SENS-601 uses an AAV vector to restore Cx26 function in cochlear supporting cells, addressing the root cause of GJB2-related hearing loss.

• Preclinical models show hearing restoration and functional gap junction recovery in Cx26 knockout mice.

• Selective transduction of supporting cells demonstrated in non-human primates, with no expression in sensory hair cells.

• Toxicology studies in mice and primates show favorable safety profile, with only minor, expected observations.